Fox Run Management’s Royalty Pharma RPRX Stock Holding History

Fox Run Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.35M	Buy	24,094 +5,379	+29%	+$280K	0.22%	91
2026 Q1	$868K	Buy	+18,715	New	+$820K	0.15%	226
2025 Q2	–	Sell	-20,646	Closed	-$643K	–	1173
2025 Q1	$643K	Sell	20,646 -34,416	-63%	-$1.09M	0.1%	382
2024 Q4	$1.4M	Buy	55,062 +16,084	+41%	+$426K	0.26%	69
2024 Q3	$1.1M	Buy	38,978 +1,383	+4%	+$38.3K	0.25%	92
2024 Q2	$991K	Buy	37,595 +12,508	+50%	+$347K	0.19%	189
2024 Q1	$762K	Buy	+25,087	New	+$740K	0.16%	230
2023 Q3	–	Sell	-7,750	Closed	-$238K	–	952
2023 Q2	$238K	Sell	7,750 -15,703	-67%	-$532K	0.07%	524
2023 Q1	$845K	Buy	23,453 +13,919	+146%	+$516K	0.28%	98
2022 Q4	$377K	Buy	+9,534	New	+$398K	0.15%	264
2022 Q2	–	Sell	-14,787	Closed	-$576K	–	718
2022 Q1	$576K	Buy	+14,787	New	+$581K	0.32%	67
2021 Q4	–	Sell	-8,659	Closed	-$313K	–	675
2021 Q3	$313K	Buy	+8,659	New	+$337K	0.2%	214

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fox Run Management's RPRX Position: Q2 2026 in Review

Fox Run Management increased its Royalty Pharma (RPRX) stake by 29% in Q2 2026, buying an estimated $280K and bringing the position to 24,094 shares worth $1.35M. The position accounts for 0.22% of the portfolio, ranked #91.

Fox Run Management first reported a position in RPRX in Q3 2021 and has held it in 12 quarters since. The position peaked at $1.4M in Q4 2024. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Fox Run Management held 24,094 shares of Royalty Pharma worth $1.35M as of Q2 2026.
Fox Run Management bought 5,379 Royalty Pharma shares in Q2 2026, an estimated $280K.
Royalty Pharma made up 0.22% of Fox Run Management's portfolio in Q2 2026, its #91 holding.
Fox Run Management first reported a position in Royalty Pharma in Q3 2021 and has held it in 12 quarters since.
Fox Run Management's Royalty Pharma position peaked at $1.4M in Q4 2024.
645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.